Who is sponsoring NCT01694017?

NCT01694017 is sponsored by Tufts University.

What drugs are being tested in NCT01694017?

Interventions: Tenofovir, Zidovudine.

What is the status of NCT01694017?

NCT01694017 is currently COMPLETED.

Last reviewed 2014-11-20 · How we verify

Economic Evaluation of Treatment of HIV With Zidovudine/Stavudine and Tenofovir Regimen: A Cost Effectiveness Study

NCT01694017 Phase 4 COMPLETED

The purpose of this study is to compare clinical, economical and quality of life (QOL) outcomes in patients living with HIV on zidovudine/stavudine regimen and tenofovir regimen. This study will be an unblinded randomized trial. The first step will be empirical data collection for one year for calculating the incremental cost effectiveness ratio (ICER). The second step will be to perform a simulation model for calculating long term ICER.

Details

Lead sponsor	Tufts University
Phase	Phase 4
Status	COMPLETED
Enrolment	68
Start date	2012-11
Completion	2014-08

Conditions

Interventions

Tenofovir
Zidovudine

Primary outcomes

Viral suppression — End of follow-up : end of 12th Month
Change in CD4 levels — End of Months 6 and 12
Drug related toxicity — Months : 1,2,3,4,5,6,7,8,9,10,11,12
opportunistic infections — Months: 1,2,3,4,5,6,7,8,9,10,11,12
Direct costs — Months: 1,2,3,4,5,6,7,8,9,10,11,12
Quality of life — Month 1 and end of months 4,8 and 12

Countries

India